GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » EBIT

MORF (Morphic Holding) EBIT : $-213.02 Mil (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding EBIT?

Morphic Holding's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was $-65.23 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was $-213.02 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Morphic Holding's annualized ROC % for the quarter that ended in Jun. 2024 was -3,014.41%. Morphic Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -4,087.60%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Morphic Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -9.52%.


Morphic Holding EBIT Historical Data

The historical data trend for Morphic Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding EBIT Chart

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -46.99 -47.18 -95.81 -63.40 -178.69

Morphic Holding Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.30 -44.75 -49.43 -53.60 -65.23

Competitive Comparison of Morphic Holding's EBIT

For the Biotechnology subindustry, Morphic Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morphic Holding's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Morphic Holding's EV-to-EBIT falls into.



Morphic Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-213.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding  (NAS:MORF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Morphic Holding's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-260.932 * ( 1 - -0.42% )/( (8.631 + 8.754)/ 2 )
=-262.0279144/8.6925
=-3,014.41 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Morphic Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-260.932/( ( (5.851 + max(1.2710000000001, 0)) + (5.645 + max(-13.211, 0)) )/ 2 )
=-260.932/( ( 7.1220000000001 + 5.645 )/ 2 )
=-260.932/6.3835
=-4,087.60 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 17.175) - (15.904 + 0 + 0)
=1.2710000000001

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 11.132) - (24.343 + 0 + 0)
=-13.211

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Morphic Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-213.016/2237.005
=-9.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding EBIT Related Terms

Thank you for viewing the detailed overview of Morphic Holding's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding Business Description

Traded in Other Exchanges
N/A
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Executives
William Devaul officer: General Counsel and Secretary C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers officer: Chief Scientific Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin officer: CFO and COO ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni director, officer: President and CEO C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr officer: VP Finance and Ops, Secretary CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery director C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer director, 10 percent owner 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde officer: Chief Medical Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda director 281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal director C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199